Cargando…
A Novel Therapy for Huntington’s Disease
In 1979, while at the National Institutes of Health, now Columbia University professor Nancy Wexler and colleagues traveled to Venezuela to study the world’s largest family with Huntington’s disease. That led to identifying the disease gene at the tip of human chromosome 4 and the race to find a dru...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Dana Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353115/ https://www.ncbi.nlm.nih.gov/pubmed/30746028 |
_version_ | 1783390962281611264 |
---|---|
author | La Spada, Albert R. |
author_facet | La Spada, Albert R. |
author_sort | La Spada, Albert R. |
collection | PubMed |
description | In 1979, while at the National Institutes of Health, now Columbia University professor Nancy Wexler and colleagues traveled to Venezuela to study the world’s largest family with Huntington’s disease. That led to identifying the disease gene at the tip of human chromosome 4 and the race to find a drug that can treat people who carry the fatal gene prior to the onset of symptoms. Our author believes that a new strategy tied to turning off targeted genes could have profound implications for therapy development for Huntington’s and other neurodegenerative diseases. |
format | Online Article Text |
id | pubmed-6353115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Dana Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-63531152019-02-11 A Novel Therapy for Huntington’s Disease La Spada, Albert R. Cerebrum Articles In 1979, while at the National Institutes of Health, now Columbia University professor Nancy Wexler and colleagues traveled to Venezuela to study the world’s largest family with Huntington’s disease. That led to identifying the disease gene at the tip of human chromosome 4 and the race to find a drug that can treat people who carry the fatal gene prior to the onset of symptoms. Our author believes that a new strategy tied to turning off targeted genes could have profound implications for therapy development for Huntington’s and other neurodegenerative diseases. The Dana Foundation 2018-09-01 /pmc/articles/PMC6353115/ /pubmed/30746028 Text en Copyright 2018 The Dana Foundation All Rights Reserved |
spellingShingle | Articles La Spada, Albert R. A Novel Therapy for Huntington’s Disease |
title | A Novel Therapy for Huntington’s Disease |
title_full | A Novel Therapy for Huntington’s Disease |
title_fullStr | A Novel Therapy for Huntington’s Disease |
title_full_unstemmed | A Novel Therapy for Huntington’s Disease |
title_short | A Novel Therapy for Huntington’s Disease |
title_sort | novel therapy for huntington’s disease |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353115/ https://www.ncbi.nlm.nih.gov/pubmed/30746028 |
work_keys_str_mv | AT laspadaalbertr anoveltherapyforhuntingtonsdisease AT laspadaalbertr noveltherapyforhuntingtonsdisease |